Skip to main content
Birkhäuser
Book cover

Aromatase Inhibitors

  • Book
  • © 2006

Overview

  • First comprehensive overview on the different aromatase inhibitors
  • Includes preclinical and clinical studies
  • Gives outlook on future uses of aromatase inhibitors
  • International authorship

Part of the book series: Milestones in Drug Therapy (MDT)

This is a preview of subscription content, log in via an institution to check access.

Access this book

eBook USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (9 chapters)

Keywords

About this book

Many breast tumours are dependent upon oestrogen for their development and continued growth. Over the last 25 years hormone therapy has progressed from the irreversible destruction of endocrine glands to the use of drugs that reversibly suppress oestrogen synthesis or action. The inhibition of oestrogen synthesis is most readily achieved by inhibiting the final step in the pathway of oestrogen biosynthesis, the reaction which transforms androgens into oestrogens by creating an aromatic ring in the steroid molecule (hence the enzyme's trivial name, aromatase).
Whereas the first aromatase inhibitors to be used therapeutically could be shown to produce drug-induced inhibition of the enzyme and therapeutic benefits in patients with breast cancer, they were not particularly potent and lacked specificity. However, second-generation drugs were developed and most recently third-generation inhibitors have evolved which possess remarkable specificity and potency. Initial results from clinical trials suggest that these agents will become the cornerstones of future endocrine therapy.

Editors and Affiliations

  • AstraZeneca, Global Discovery, Macclesfield, Cheshire, UK

    Barrington J.A. Furr

Bibliographic Information

Publish with us